Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 1/2 1Phase 1 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Esophageal Neoplasms 2Nasopharyngeal Carcinoma 1Esophageal Squamous Cell Carcinoma 1Advanced Solid Tumor 1

Interventions

Paclitaxel 10Radiotherapy 7Fluorouracil 7pembrolizumab 6Carboplatin 6Oxaliplatin 5Cisplatin 5lenvatinib 3Neoadjuvant Therapy 3Cetuximab 3tislelizumab 2camrelizumab 2Surgical Procedures, Operative 2Nivolumab 2Leucovorin 2Irinotecan 2Drug Therapy 2Docetaxel 2tremelimumab 1toripalimab 1regorafenib 1osimertinib 1oblimersen 1nimotuzumab 1nedaplatin 1monalizumab 1enzalutamide 1durvalumab 1aflibercept 1abiraterone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Esophageal Squamous Cell Carcinoma × nedaplatin × Clear all
NCT06010212 2023-08-24

Fruquintinib as First Line Treatment in Patients With Recurrent Esophageal Squamous Cell Carcinoma

The First Affiliated Hospital with Nanjing Medical University

Phase 1/2 Not yet recruiting
36 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡